A step in the right direction, but the challenge gets even more interesting: usually, the way insurance remains profitable (or even possible) in a market economy is that those with the highest risk pay the largest premiums. Except, when it comes to antibiotics, those at greatest risk (third-world countries) are also those least able to pay their fair share, let alone a correspondingly larger portion.

A tough nut to crack for sure...